P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation.
P2X1 receptors are ATP-gated channel demonstrated to be involved in multiple platelet responses, although in vitro analysis has been complicated by the effects of rapid desensitization. To further investigate potential roles of P2X1 receptors in platelet activation, the current study employed methods which maximally preserved P2X1 functionality. In preliminary in vivo studies, P2X1-deficiency reduced thrombus formation following the laser-induced, but not FeCl3-induced injury. Given the multiple potential mechanisms involved in thrombus formation in vivo, including tissue-factor/thrombin generation pathways, subsequent studies were designed to investigate the effects of P2X1 inhibition or stimulation on platelet activation in vitro; specifically, the interaction of P2X1 with thrombin receptor stimulation. Aggregation initiated by low/threshold levels of a protease-activated receptor (PAR)4 agonist was reduced in P2X1-deficient murine platelets, and inhibition of P2X1 in wild-type platelets similarly reduced PAR4-mediated aggregation. In human platelets, aggregation to low/threshold stimulation of PAR1 was inhibited with the P2X1 antagonist MRS2159. In addition, P2X1 stimulation primed human platelet responses, such that subsequent sub-threshold PAR1 responses were converted into significant aggregation. Selective ADP receptor inhibitors attenuated P2X1-mediated priming, suggesting that the synergy between P2X1 and sub-threshold PAR1 stimulation was in part because of enhanced granular release of ADP. Overall, the present study defines a novel interaction between platelet P2X1 and thrombin receptors, with P2X1 functioning to amplify aggregation responses at low levels of thrombin receptor stimulation.
Erhardt
J A
JA
GlaxoSmithKline, Department of Vascular Biology, King of Prussia, PA 19406, USA. joseph_a_erhardt@gsk.com
Toomey
J R
JR
Douglas
S A
SA
Johns
D G
DG
D000818:Animals; D001792:Blood Platelets / Q000378:metabolism; D002712:Chlorides; D005290:Ferric Compounds / Q000494:pharmacology; D006801:Humans; D007834:Lasers; D051379:Mice; D010974:Platelet Aggregation; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000378:metabolism*; D058469:Receptors, Purinergic P2X; D018179:Receptors, Thrombin / Q000378:metabolism*; D013045:Species Specificity; D013927:Thrombosis / Q000378:metabolism
D002712:Chlorides; D005290:Ferric Compounds; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058469:Receptors, Purinergic P2X; D018179:Receptors, Thrombin; C024555:ferric chloride